Form 8-K · Current Report · Filed 2025-08-11
Roivant Reports Q1 2025 Financial Results and Provides Business Update
Roivant Sciences Ltd. reported financial results for the first quarter of 2025, with a net loss of $273.9 million from continuing operations and a consolidated cash position of $4.5 billion. The company also completed its $1.5 billion share repurchase program and approved a new $500 million buyback. Roivant provided updates on its clinical trials, including progress in its Phase 3 VALOR study for brepocitinib in dermatomyositis, which is on track for topline data readout in the second half of 2025. Additionally, Immunovant, a subsidiary, initiated two new potentially registrational trials for IMVT-1402 in Graves' disease and Sjögren's disease in June 2025. Roivant will host a conference call on August 11, 2025, to discuss these results and provide a corporate update.
- Filer
- Roivant Sciences Ltd ROIV · NASDAQ
- Filed
- Accession
- 0001140361-25-029998
- CIK
- 0001635088
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$11.49
Next session
+0.7%
Since filing
+201.5%
Latest close
$34.64
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ROIV reporting the same item, with the next session's move:
Exhibits (1)
About Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.
Never miss another ROIV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.